TOKYO and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase ...
- Sosei Heptares will receive an upfront payment of US$10 million, plus downstream payments of up to US$370 million, plus tiered royalties TOKYO and CAMBRIDGE, England, Dec. 1, 2020 /PRNewswire/ -- ...
Zavegepant, an investigational nasal spray formulation of a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, met its co-primary endpoints in a phase III randomized ...
Biohaven Pharmaceutical is eyeing filing for approval early next year for its experimental pain spray after new data showed it hit its primary endpoints in a phase 3 test. The drug, the small-molecule ...
In 2011, Merck & Co. discontinued a once promising program to develop a new kind of drug to treat and prevent migraines. The biological rationale behind telcagepant—a small-molecule inhibitor of the ...
Peter Goadsby sat in the audience, intrigued. The Australian medical student had come to Lund, Sweden, for a conference in June 1985. He was studying migraine, and during this particular talk about ...
For Cherise Irons, chocolate, red wine and aged cheeses are dangerous. So are certain sounds, perfumes, cold weather and thunderstorms. Stress and lack of sleep, too. She suspects all of these things ...
June 6, 2011 – (Rensselaer, N.Y., USA) – A new study may explain why only 50% of patients experiencing chronic nerve pain achieve even partial relief from existing therapeutics. The study, published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results